Famotidine treatment of children with autistic spectrum disorders: Pilot research using single subject research design

Journal of Neural Transmission

Volumn 108, Issue 5, 2001, Pages 593-611

  Linday, L A ^a,b,c,f   Tsiouris, J A ^c   Cohen, I L ^c   Shindledecker, R ^d   DeCresce, R ^e  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Columbia University ^*  (United States)

^c IBR   (United States)

^d Iona C Grad Sch of Arts and Sci   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f NONE   (United States)

Author keywords

Autism; Histamine 2 receptor antagonist; Pervasive developmental disorder

Indexed keywords

FAMOTIDINE; ORA PLUS; PLACEBO;

ARTICLE; AUTISM; BEHAVIOR; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVELOPMENTAL DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION;

AUTISTIC DISORDER; BODY WEIGHT; BRAIN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FAMOTIDINE; HISTAMINE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; PILOT PROJECTS; RECEPTORS, HISTAMINE H2; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0035030948     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170059     Document Type: Article

References (65)

1. Accardo PJ, Roseman B (2000) By any other name [editorial]. J Pediatr 136: 576-577
2. Aitken RCB (1969) Measurement of feelings using visual analogue scales. Proc Roy Soc Med 62: 989-993
3. Alvarez EO, Guerra FA (1982) Effects of histamine microinjections into the hippocampus on open-field behavior in rats. Physiol Behav 28: 1035-1040
4. Aman MG, Singh NN (1986) Manual for the aberrant behavior checklist. Slosson Educational Publications, East Aurora, New York
5. Aman MG, Singh NN (1994) Supplementary manual for the aberrant behavior checklist - community. Slosson Educational Publications, East Aurora, New York
6. Aman MG, Singh NN, Stewart AW, Field C (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89: 485-491
7. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington, DC
8. Bauman ML (1996) Brief report: neuroanatomic observations of the brain in pervasive developmental disorders. J Autism Dev Disord 26: 199-203
9. Bauman M, Kemper TL (1985) Histoanatomic observations of the brain in early infantile autism. Neurology 35: 866-874
10. Bauman ML, Kemper TL (eds) (1994) The neurobiology of autism. Johns Hopkins University Press, Baltimore
11. Campbell M, Harris JC (1996) Debate forum: Resolved: autistic children should have a trial of naltrexone. J Am Acad Child Adolesc Psychiatry 35: 246-251
12. Campbell M, Small AM, Hollander CS, Korein J, Cohen IL, Kalmijn M, Ferris S (1978) A controlled crossover study of triiodothyronine in autisitic children. J Autism Childhood Schizophr 8: 371-381
13. Carroccio A, Pardo F, Montalto G, Iapichino L, Soresi M, Averna MR, Iacono G, Notarbartolo A (1992) Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy; a long-term study in cystic fibrosis. Dig Dis Sci 37: 1441-1446
14. Cohen IL, Anderson LT, Campbell M (1978) Measurement of drug effects in autistic children. Psychopharmacol Bull 14: 68-70
15. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson L (1980) Behavioral effects of haloperidol in young autistic children. J Am Acad Child Psychiatry 19: 665-677
16. Cohen IL, Vietze PM, Sudhalter V, Jenkins EC, Brown WT (1989) Parent-child dyadic gaze patterns in fragile X males and in non-fragile X males with autistic disorder. J Child Psychol Psychiat 30: 845-856
17. Cook DJ (1996) Randomized trials in single subjects: the N of 1 study. Psychopharmacol Bull 32: 363-367
18. th edn II. Oxford University Press, New York, pp 338-380
19. Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M, Collins Jr JP, Wyatt RJ (1993) Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 16: 518-524
20. Franklin RD, Allison DB, Gorman BS (eds) (1997) Design and analysis of single-case research. Lawrence Erlbaum Associates, Mahwah
21. nd edn. Oxford, New York
22. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT (1990) The N-of-1 randomized controlled trial: clinical usefulness. Ann Intern Med 112: 293-299
23. th edn. WB Saunders, Philadelphia
24. Halpern LM, Jolley SG, Johnson DG (1991) Gastroesophageal reflux: a significant association with central nervous system disease in children. J Pediatr Surg 26: 171-173
25. Hebra A, Hoffman MA (1993) Gastroesophageal reflux in children. Pediatr Clin North Am 40: 1233-1251
26. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT (1998) Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Min Phys 9: 9-15
27. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT (1999) Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 135: 559-563
28. Kagevi I, Thorhallsson E, Wählby L (1987) CSF concentrations of famotidine. Br J Clin Pharmacol 24: 849-850
29. Kanakia RR, Sawant PD, Nanivadekar SA, Vishwanath N, Rajogopalan K, Shroff CP (1994) Primary gastrinoma of the liver. Pediatr Surg 31: 1137-1140
30. Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M (1990) Effect of famotidine on deficit symptoms of schizophrenia [letter]. Lancet 335: 1351-1352
31. Kazdin AE (1982) Single-case research designs. Oxford University Press, New York
32. Klein RG, Abikoff H, Barkley RA, et al (1994) Clinical trials in children and adolescents. In: Prien RE, Robinson DS (eds) Clinical evaluation of psychotropic drugs: principles and guidelines. Raven Press, New York, pp 501-546
33. Kolmen BK, Feldman HM, Handen BL, Janosky JE (1997) Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 36: 1570-1578
34. Kutcher SP (1997) Child and adolescent psychopharmacology. WB Saunders, Philadelphia
35. Langtry HD, Grant SM, Goa KL (1989) Famotidine, an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 38(4): 551-590
36. Liddle RA (1995) Chemical messengers of the gut [editorial]. West J Med 163: 485-486
37. Linday LA (1997) Oral famotidine: a potential treatment for children with autism. Med Hypotheses 48: 381-386
38. 2-blocker, famotidine, in reflux esophagitis among severely handicapped children. Clin Ther 9: 548-558
39. Molinari SP, Kaminski R, DiRocco A, Yahr MD (1995) The use of famotidine in the treatment of Parkinson's disease: a pilot study. J Neural Transm [P-D Sect] 9: 243-247
40. Munro BH, Page EB (1993) Statistical methods for health care research, 2nd edn. JB Lippincott, Philadelphia
41. Nagita A, Manago M, Aoki S, Mino M, Suzuki K, Ashida K (1994) Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit 16: 444-449
42. National Institute of Mental Health (1985) Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21: 839-843
43. Oderda G, Dell'Olio D, Forni M, Farina L, Tavassoli K, Ansaldi N (1990) Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid. Ital J Gastroenterol 22: 346-349
44. Owley T, Steele E, Corsello C, et al (1999) A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape GeneralMedicine (http://www.medscape.com/medscape/GeneralMedicine/jounral/1999 /v0.1n10mgm1006.owle/mgm1006.owle-0.1.html)
45. Oyewumi LK, Vollick D, Merskey H, Plumb C (1994) Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatr Neurosci 19: 145-150
46. th edn (2000) Medical Economics Company, Montvale (NJ) (Pepcid; pp 1852-5)
47. Prell GD, Green JP (1986) Histamine as a neuroregulator. Ann Rev Neurosci 9: 209-254
48. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14: 93-104
49. Rapin I (1997) Autism. N Engl J Med 337: 97-104
50. Rosse RB, Kendrick K, Tsui LC, Fay-McCarthy M, Collins Jr JP, Rosenberg P, Wyatt RJ, Deutsch SI (1995) Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin Neuropharmacol 18: 369-374
51. Rosse RB, Kendrick K, Fay-McCarthy M, Prell GP, Rosenberg P, Tsui LC, Wyatt RJ, Deutsch SI (1996) An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 19: 341-348
52. Sandler AD, Sutton KA, DeWeese J, Girardi A, Sheppard V, Bodfish JW (1999) Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 341: 1801-1806
53. Schopler E, Reichler RJ, Renner BR (1988) CARS. The Childhood Autism Rating Scale. Western Psychological Services, Los Angeles, CA
54. Scott J, Huskisson EC (1976) Graphic representation of pain. Pain 2: 175-184
55. Schwartz J-C, Arrang J-M, Gargarg M, Traiffort E (1995) Histamine. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 397-405
56. nd edn. McGraw-Hill, New York
57. Statistica, Release 5.5, '99 Edition (1999) StatSoft, Tulsa
58. Straus JL, Cavanaugh von Ammon S (1996) Placebo effects; issues for clinical practice in psychiatry and medicine. Psychosomatics 37: 315-326
59. Strayhorn JM (1994) The vitamin and mineral mystery. J Am Acad Child Adolesc Psychiatry 33: 1346-1347
60. Wada H, Inagaki N, Yamatodani A, Watanabe T (1991) Is the histaminergic neuron system a regulatory center for whole-brain activity?Trends Neurosci 14: 415-418
61. Whiteford HA, Stedman TJ, McGrath JJ, Welham J, Pond S (1995) An open-label study of famotidine as a treatment for schizophrenia [letter]. J Psychiatry Neurosci 20: 239-240
62. Willemsen-Swinkels SHN, Buitelaar JK, van Engeland H (1996) The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 39: 1023-1031
63. Wirz-Justice A (1995) Biological rhythms in mood disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 999-1017
64. Yee LF, Mulvihill SJ (1995) Neuroendocrine disorders of the gut. West J Med 163: 454-462
65. Zealley AK, Aitken RCB (1969) Measurement of mood. Proc Roy Soc Med 62: 993-996